Visacor

País: Nova Zelanda

Idioma: anglès

Font: Medsafe (Medicines Safety Authority)

ingredients actius:

Rosuvastatin calcium 20.8mg equivalent to 20 mg rosuvastatin;  

Disponible des:

AstraZeneca Limited

Designació comuna internacional (DCI):

Rosuvastatin calcium 20.8 mg (= 20 mg rosuvastatin)

Dosis:

20 mg

formulario farmacéutico:

Film coated tablet

Composición:

Active: Rosuvastatin calcium 20.8mg equivalent to 20 mg rosuvastatin   Excipient: Calcium phosphate Crospovidone Hypromellose as Opadry Pink Iron oxide red as Opadry Pink Lactose monohydrate as Opadry Pink   Magnesium stearate Microcrystalline cellulose Titanium dioxide as Opadry Pink Triacetin as Opadry Pink

Unidades en paquete:

Blister pack, Al/Al foil, 30 tablets

clase:

Prescription

tipo de receta:

Prescription

Fabricat per:

AstraZeneca UK Ltd

indicaciones terapéuticas:

VISACOR is indicated to: - Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDLcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). - Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia). Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (eg. LDL apheresis) or alone if such treatments are unavailable.

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, Al/Al foil - 30 tablets - 36 months from date of manufacture stored at or below 30°C

Data d'autorització:

2009-07-31